Sugi Predict

Sugi Predict / Compounds / SCHEMBL30923988

SCHEMBL30923988

SCHEMBL30923988

CC(C)(C)OC(=O)N1C[C@@H](NS(C)(=O)=O)C(F)(F)[C@H]1CO

nearest known ligand 0.36

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 7/20 0.36
▸ HCRTR2 O43614 1/20 0.35
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ NR1H3 Q13133 5/20 0.32
▸ TACR1 P25103 4/20 0.32
▸ HSD11B1 P28845 1/20 0.31
▸ SCN9A Q15858 1/20 0.31
▸ GPR119 Q8TDV5 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30924005 0.91 HCRTR2 (0.34) NR1H2HCRTR2NR1H3HSD11B1SCN9A
SCHEMBL30923940 0.87 HCRTR2 (0.34) NR1H2HCRTR2NR1H3SCN9A
SCHEMBL30924012 0.80 NR1H2 (0.34) NR1H2HSD11B1
SCHEMBL30924050 0.79 HCRTR2 (0.42) NR1H2HCRTR2NR1H3TACR1GPR119
SCHEMBL30924048 0.79 HCRTR2 (0.42) NR1H2HCRTR2NR1H3TACR1GPR119
SCHEMBL30923983 0.78 KDM1A (0.33) NR1H2HCRTR2MEN1KMT2AHSD11B1
SCHEMBL30923970 0.77 NR1H2 (0.34) NR1H2NR1H3
SCHEMBL30923972 0.77 NR1H2 (0.34) NR1H2NR1H3
SCHEMBL30923955 0.77 NR1H2 (0.41) NR1H2MEN1KMT2ATACR1
SCHEMBL30954988 0.73 NR1H2 (0.38) NR1H2SCN9AGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122071471-A Heterocyclic compounds 武田药品工业株式会社 2026-05-22 — — CN disclosed
CN-122010946-A Heterocyclic compounds 武田药品工业株式会社 2026-05-12 — — CN disclosed
CN-122010945-A Heterocyclic compounds 武田药品工业株式会社 2026-05-12 — — CN disclosed
US-12534471-B2 Pyrrolo[1, 2-c]imidazole derivatives as orexin type 2 receptor agonists and methods of use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2026-01-27 — — US disclosed
EP-4612145-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2025-09-10 — — EP disclosed
US-20240317765-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-09-26 — — US disclosed
US-20240174677-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-05-30 — — US disclosed
WO-2024095133-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-05-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317765-A1 HETEROCYCLIC COMPOUND HCRTR2, HCRTR1, NPY2R NR1H2 170/4885HCRTR2 1/4885MEN1 665/4885
US-20240174677-A1 HETEROCYCLIC COMPOUND HCRTR2, HCRTR1, NPY2R NR1H2 170/4885HCRTR2 1/4885MEN1 665/4885
US-12534471-B2 Pyrrolo[1, 2-c]imidazole derivatives as orexin type 2 receptor agonists and methods of use thereof HCRTR2, HCRTR1, NPY1R NR1H2 79/4885HCRTR2 1/4885MEN1 1690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.